查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1881712

痛風治療市場－全球產業規模、佔有率、趨勢、機會和預測，按藥物類型、配銷通路、地區和競爭格局分類（2020-2030 年預測）

Gout Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel, By Region, By Competition 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球痛風治療市場規模為21.6億美元，預計2030年將以8.8%的複合年成長率成長至35.8億美元。痛風治療藥物包括專門用於控制痛風急性和慢性症狀的藥物介入。痛風是一種發炎性關節炎，其特徵是尿酸鈉晶體沉積在關節內。這些治療方法的主要目標是降低血清尿酸水平並減輕發炎反應。痛風在全球的盛行率不斷上升，而人口老化以及肥胖和高血壓等相關代謝合併症發病率的增加，顯著推動了該市場的成長。

市場概覽
預測期 2026-2030
2024年市場規模 21.6億美元
2030年市場規模 35.8億美元
2025-2030年複合年成長率 8.8%
成長最快的細分市場 降尿酸藥物
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球痛風治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型（非類固醇抗發炎藥、秋水仙鹼、降尿酸藥物、生物製劑）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美痛風治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲痛風治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區痛風治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲痛風治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲痛風治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球痛風治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Abbott Laboratories Inc
  • Medtronic Plc
  • Boston Scientific Corp
  • Becton, Dickinson and Company
  • Novartis AG
  • GlaxoSmithKline plc
  • Allergen, Inc.
  • WL Gore & Associates, Inc.
  • Stryker Corporation
  • Terumo Corporation

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 21431

The Global Gout Therapeutics Market, valued at USD 2.16 Billion in 2024, is projected to experience a CAGR of 8.8% to reach USD 3.58 Billion by 2030. Gout therapeutics comprise pharmaceutical interventions explicitly designed to manage the acute and chronic manifestations of gout, an inflammatory arthritic condition characterized by the deposition of monosodium urate crystals within joints. These treatments primarily aim to reduce serum uric acid levels and mitigate inflammatory responses. The market's expansion is significantly driven by the escalating global prevalence of gout, exacerbated by an aging population and the increasing incidence of associated metabolic comorbidities, such as obesity and hypertension.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.16 Billion
Market Size 2030USD 3.58 Billion
CAGR 2025-20308.8%
Fastest Growing SegmentUrate-lowering Drugs
Largest MarketNorth America

Key Market Drivers

The escalating global prevalence of gout represents a primary catalyst for market expansion in gout therapeutics. This inflammatory condition, driven by various factors including an aging population and lifestyle changes, continues to affect a substantial portion of the worldwide populace. According to a study published in *The Lancet Rheumatology*, in July 2024, 55.8 million people globally had gout in 2020, with projections indicating a significant increase over the coming decades. This rising patient demographic directly translates into an increased demand for effective diagnostic tools and a broad spectrum of treatment modalities, ranging from acute flare management to long-term urate-lowering therapies, placing considerable pressure on healthcare systems to provide comprehensive care.

Key Market Challenges

A significant challenging factor impeding the growth of the Global Gout Therapeutics Market is the high cost associated with advanced therapeutic options, coupled with restrictive reimbursement policies. These financial barriers directly limit patient access to innovative and effective treatments, especially in regions with developing economies. When patients cannot afford or access necessary medications due to prohibitive pricing or insufficient insurance coverage, market penetration for these therapies is severely curtailed.

Key Market Trends

The Global Gout Therapeutics Market is currently experiencing a significant shift towards more specialized and advanced treatment modalities. This includes a notable trend in the increasing focus on targeted biologic therapies, which offer more precise mechanisms of action compared to conventional treatments. These therapies aim to address specific pathways involved in gout pathogenesis, particularly for patients who do not respond adequately to traditional urate-lowering agents. According to MedCity News, on July 19, 2024, GRO Biosciences raised $60 million in Series B financing to advance its engineered protein technology for gout, aiming to overcome immune response limitations of existing biologic treatments.

Key Market Players

  • Abbott Laboratories Inc
  • Medtronic Plc
  • Boston Scientific Corp
  • Becton, Dickinson and Company
  • Novartis AG
  • GlaxoSmithKline plc
  • Allergen, Inc.
  • W. L. Gore & Associates, Inc.
  • Stryker Corporation
  • Terumo Corporation

Report Scope:

In this report, the Global Gout Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gout Therapeutics Market, By Drug Type:

  • NSAIDs
  • Colchicine
  • Urate-lowering Drugs
  • Biologics

Gout Therapeutics Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Gout Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Gout Therapeutics Market.

Available Customizations:

Global Gout Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gout Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (NSAIDs, Colchicine, Urate-lowering Drugs, Biologics)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Gout Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gout Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Gout Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Gout Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Gout Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gout Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Gout Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Gout Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Gout Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Gout Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Gout Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gout Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Gout Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Gout Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Gout Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Gout Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Gout Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Gout Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Gout Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Gout Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Gout Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gout Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Gout Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Gout Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gout Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Medtronic Plc
  • 15.3. Boston Scientific Corp
  • 15.4. Becton, Dickinson and Company
  • 15.5. Novartis AG
  • 15.6. GlaxoSmithKline plc
  • 15.7. Allergen, Inc.
  • 15.8. W. L. Gore & Associates, Inc.
  • 15.9. Stryker Corporation
  • 15.10. Terumo Corporation

16. Strategic Recommendations

17. About Us & Disclaimer